MedDataX Logo

Systematic Workflow for Pentaspline Pulsed-field Ablation Optimization: Real-world Performance of the 12 COmmandments (12-O) Strategy

NCT ID: NCT06706518

Last Updated: 2024-12-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

108 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-08-17

Study Completion Date

2024-11-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In our center we have developed a systematic approach to pulmonary vein cryoablation (SWEET Cryo strategy) that has been shown to reduce radiation during the procedure substantially without increasing the cost associated with the procedure. This study, however, has been done on the basis of pulmonary vein cryoablation technology available on the market in the last 10 years. The appearance of new cryoablation technologies (greater degree of sheath deflection, greater balloon catheter complexity, balloon with expandable diameter) and new energy sources, such as pulsed electric field ablation or "electroporation" for "single shot" ablation, which significantly modify the workflow during the procedure, raises the question of whether the strategy developed and validated in our center is applicable to these other technologies, which are already being used in our center.

Specifically in relation to pulsed electric field ablation, the question arises as to the impact that a fluoroscopy reduction strategy may have on clinical outcomes. This is due to the need for catheter contact with the tissue, which in the case of cryoablation is guaranteed by verification of vein occlusion (contrast retention) but which in this new technology is not, since the vein is not occluded and therefore there is no possibility of verification of contact with the tissue by this means. Thus, the use of X-rays is the best way to estimate the degree of contact, which determines the durability of the treatment in the long term. In this regard, there are discordant data in different series of the initial application of this technology. While the initial evidence showed between 96 and 100% durability of pulmonary vein isolation, recent registries on the real-life application of this technology show reconnection of at least one pulmonary vein in 28% of patients undergoing re-intervention for clinical recurrence of atrial fibrillation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this study is the comparison of fluoroscopy time and dose-area product (DAP) between the different single-shot ablation technologies available in our center after application of the "SWEET" strategy for reducing X-ray exposure. Secondary objectives are efficacy and safety outcomes.

The hypothesis is that this systematic approach allows a significant reduction in the radiation used in this procedure in all single-shot techniques, while maintaining its efficacy and safety.

The secondary hypothesis is that the reduction of fluoroscopy during the procedure does not obtain worse results in terms of durability of pulmonary vein isolation with respect to what is reported in routine clinical practice registries.

Taking into account previous data from the experience in our center, it is considered that, in order to obtain a representative sample, not conditioned by extreme values of cases with punctual particularities, of fluoroscopy and PDA time values, data from 40 patients with each technique should be collected and analyzed:

* 31 mm Farawave catheter ablation using pulsed electric fields. This catheter will be used in patients with resting heart rate \>70 bpm in whom it is estimated that there is less likely to be a vagotonic component in AF perpetuating mechanisms, since the energy source does not act on cardiac ganglionic plexuses.
* PolarFit balloon catheter with adjustable diameter 28 to 31 mm. This catheter will be used in patients with persistent AF and dilated left atrium, where the ability to encompass more of the atrial myocardium at the level of the antrum of the pulmonary veins allows a greater number of potential AF perpetuating regions to be covered.
* ArcticFront Advance Pro 28 mm diameter balloon catheter\*.
* 28 mm diameter PolarX balloon catheter\*.

* These last two catheters will be used indistinctly in patients who do not present the previously mentioned characteristics-.

Ablation will be performed according to standard clinical practice, with the only difference being the application of this protocol to minimize the use of radiation.

Patient demographic variables will be collected, preserving the anonymity of the data by assigning a specific code for the study and not linked to the patient's medical history number or other identifying data.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation (Paroxysmal) Atrial Fibrillation (AF) Ablation of Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Paroxysmal or persistent AF diagnosis and a PVI clinical indication

Patients \>18 years old, with a diagnosis of paroxysmal or persistent AF and a clinical indication to undergo PVI

Single-shot ablation technologies

Intervention Type PROCEDURE

Comparison of fluoroscopy time and dose-area product (DAP) between different single-shot ablation technologies.

* PolarFit balloon catheter with adjustable diameter 28 to 31 mm. This catheter will be used in patients with persistent AF and dilated left atrium, where the ability to encompass more of the atrial myocardium at the level of the antrum of the pulmonary veins allows a greater number of potential AF perpetuating regions to be covered.
* ArcticFront Advance Pro 28 mm diameter balloon catheter\*.
* 28 mm diameter PolarX balloon catheter\*.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Single-shot ablation technologies

Comparison of fluoroscopy time and dose-area product (DAP) between different single-shot ablation technologies.

* PolarFit balloon catheter with adjustable diameter 28 to 31 mm. This catheter will be used in patients with persistent AF and dilated left atrium, where the ability to encompass more of the atrial myocardium at the level of the antrum of the pulmonary veins allows a greater number of potential AF perpetuating regions to be covered.
* ArcticFront Advance Pro 28 mm diameter balloon catheter\*.
* 28 mm diameter PolarX balloon catheter\*.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients \>18 years old, with a diagnosis of paroxysmal or persistent AF and a clinical indication to undergo PVI were included

Exclusion Criteria

* prior PVI or left atrial linear ablation
* severe frailty or life expectancy \<1 year
* unwillingness or inability to provide informed consent
* ablation at sites beyond PVI
* contraindication or intolerance to heparin
* presence of left atrial thrombus
* congenital heart disease
* pregnancy, ongoing or planned in the following 6 months.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Daniel Rodríguez Muñoz

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Daniel Rodríguez Muñoz

Cardiologist, Head of Cardiac Electrophysiology

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Universitario 12 de Octubre

Madrid, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SWEET-Shot

Identifier Type: -

Identifier Source: org_study_id